| GTO ID | GTC1826 |
| Trial ID |
NCT03361748
|
| Disease |
Multiple Myeloma
|
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Abecma|bb2121|BMS-986395|Idecabtagene vicleucel|ide-cel |
| Location approved | US, Canada, EU, UK, Japan, Israel, Switzerland |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma |
| Year | 2017 |
| Country | Belgium|Canada|France|Germany|Italy|Japan|Spain|United States |
| Company sponsor | Celgene |
| Other ID(s) | BB2121-MM-001|U1111-1202-5554|2017-002245-29 |